erdafitinib
janssen
['solid tumor', 'erdafitinib']
erdafitinib shows promising objective response rates in fgfr-altered advanced or metastatic solid tumors &amp; difficult-to-treat malignancies. #asco22 #ascodailynews
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.